GSK2398852 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス2

28. 全身性アミロイドーシス


臨床試験数 : 261 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-000276-23-GB
(EUCTR)
06/12/201611/07/2016Study to look at the affect of anti-SAP treatment in patients with cardiac amyloidosis A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis Systemic amyloidosis
MedDRA version: 20.0;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders
MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: GSK2315698
Product Code: GSK2315698
INN or Proposed INN: miridesap
Other descriptive name: CPHC (carboxy pyrrolidine hexanoyl pyrrolidone carboxylate)
Product Name: GSK2398852
Product Code: GSK2398852
INN or Proposed INN: dezamizumab
GlaxoSmithKline Research & Development LtdNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;United Kingdom
2NCT01777243
(ClinicalTrials.gov)
May 13, 201324/1/2013A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic AmyloidosisA Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic AmyloidosisAmyloidosisDrug: GSK2398852;Drug: GSK2315698GlaxoSmithKlineImperial College London;Heart Hospital;Royal Free Hospital NHS Foundation Trust;Quintiles, Inc.Completed18 Years70 YearsAll25Phase 1United Kingdom